A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC)

Status Completed

Clinical Trial Summary

The objective of the proposed research is to investigate how smoking increasing potency of THC (i.e., the psychoactive ingredient in marijuana) changes tobacco cigarette smoking behavior, urges, subjective effects, and abuse liability. This study will be a within-subjects, placebo-controlled study in our clinical laboratory of the effect of active vs. placebo marijuana on cigarette puff topography, exhaled carbon monoxide, urge, subjective effects, and abuse liability among 7 adults who smoke both marijuana and tobacco cigarettes.

Clinical Trial Description

The study requires a total of three visits to Battelle's laboratory: one screening visit and two experimental visits. The screening visit will determine eligibility into the study. If eligible, participants will smoke a tobacco cigarette through the Clinical Research Support System (CReSS) puff topography device. Enrolled participants will attend two separate 5-hour experimental visits. Participants will be randomly assigned the order of THC potency (active or placebo), with the assignment blocked by sex. When participants arrive at the laboratory for each visit, they will provide biologic samples to verify compliance with pre-study instructions and then will be taken to a specially ventilated smoking chamber. They will be connected to a continuously-monitoring heart rate and blood pressure machine so that their vital signs can be observed throughout the smoking session. A research assistant will give a marijuana cigarette to the participant. A research assistant will light the cigarette and then exit the room. Participants will follow tape-recorded instructions for smoking the marijuana cigarette through the CReSS device. Upon completion of smoking the marijuana cigarette, participants will complete the Tobacco Craving Questionnaire via paper and pencil and will then be allowed to smoke one of his own tobacco cigarettes through the CReSS puff topography device. Participants will be allowed to smoke as many tobacco cigarettes as they would like for the next 3 hours. Participants will then be given lunch and sent home via taxicab. All participants will receive both potencies (i.e., active and placebo) of marijuana. The active potency of marijuana will be 5.6% THC. ;

Study Design

Related Conditions & MeSH terms

Tobacco Use

Clinical Trial Details

NCT number	NCT02961309
Study type	Interventional
Source	Battelle Memorial Institute
Contact
Status	Completed
Phase	Phase 1
Start date	May 7, 2018
Completion date	September 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Recruiting	`NCT06033599` - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement	Phase 3
Enrolling by invitation	`NCT05415371` - Persistent Poverty Counties Pregnant Women With Medicaid	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Completed	`NCT06105424` - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability	N/A
Completed	`NCT01311830` - Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons	N/A
Completed	`NCT04566198` - Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)
Completed	`NCT04107779` - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS	N/A
Completed	`NCT05092919` - The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults	Early Phase 1
Terminated	`NCT05274217` - Journey of Transformation Curriculum for Native American Adolescents	N/A
Enrolling by invitation	`NCT06042361` - Enhancing Equity in Smoke-free Housing	N/A
Withdrawn	`NCT03352635` - Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core	N/A
Completed	`NCT03235713` - EMA for Tobacco Control Policy Research
Completed	`NCT03151421` - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home	N/A
Completed	`NCT03446170` - Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers	N/A
Completed	`NCT04104152` - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting	N/A
Not yet recruiting	`NCT05999383` - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration	Phase 2
Recruiting	`NCT04429568` - THC Crossover Study	N/A
Completed	`NCT04632030` - Shrinking the Size of the Tobacco Power Wall	N/A
Completed	`NCT04143256` - Evaluating Selected Constituents in the Exhaled Breath Samples	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking — MJCIG

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms